Bellerophon Therapeutics Inc (BLPH.OQ)
25 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2016||Chairman of the Board, President|
|42||2016||Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director|
|40||2018||Chief Financial Officer|
|65||2014||Chief Scientific Officer, Vice President|
|54||2014||Vice President, Chief Clinical Development Officer and Secretary|
- BRIEF-Bellerophon Therapeutics Q1 Shr Loss $0.04
- BRIEF-Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse
- BRIEF-Bellerophon Q4 Loss Per Share $0.44
- BRIEF-Bellerophon Says Over 100 Patients In Late-Stage Study Testing Inopulse For Treatment Of High Blood Pressure
- BRIEF-Bellerophon Says First Patient Enrolled In Phase 2B Study Evaluating Inopulse For Treating Pulmonary Hypertension